Related Experiment Video

Updated: Jun 14, 2026

Angiogenesis in the Ischemic Rat Lung
07:36

Angiogenesis in the Ischemic Rat Lung

Published on: February 8, 2013

Anti-angiogenesis drugs in lung cancer

Siow Ming Lee1, Paul Baas, Heather Wakelee

  • 1University College London Hospital and UCL Cancer Institute, London, Department of Oncology, University College Hospital, London, UK. sm.lee@uclh.nhs.uk

Respirology (Carlton, Vic.)
|March 27, 2010
PubMed

Insights

Targeted anti-angiogenic drugs show mixed results in lung cancer treatment. This review examines the advantages and disadvantages to aid physicians in making informed therapeutic decisions.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Targeted therapies represent a significant advancement in cancer treatment.
  • Tumor vasculature is a key target, leading to the development of anti-angiogenic drugs.

Purpose of the Study:

  • To review the pros and cons of anti-angiogenic drugs in lung cancer.
  • To assist physicians in treatment selection.

Main Methods:

  • Literature review of studies on anti-angiogenic drugs in lung cancer.

Main Results:

  • Studies on anti-angiogenic drugs in lung cancer have yielded both positive and negative outcomes.
  • The efficacy and safety profiles vary, necessitating careful consideration.

Conclusions:

  • Anti-angiogenic drugs offer potential benefits but also present challenges in lung cancer management.
  • Informed decision-making by physicians is crucial for optimal patient care.

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.